checkAd

     227  0 Kommentare RedHill Biopharma Adds Israel Rights to Movantik From AstraZeneca - Seite 4

    Company contact:
    Adi Frish
    Senior VP Business Development & Licensing
    RedHill Biopharma
    +972-54-6543-112
    adi@redhillbio.com
    IR contact (U.S.):
    Timothy McCarthy, CFA, MBA
    Managing Director, Relationship Manager
    LifeSci Advisors, LLC
    +1-212-915-2564
    tim@lifesciadvisors.com

    _______________
    i Full prescribing information for Movantik (naloxegol) is available at: www.Movantik.com; Approved in Israel under brand name Moventig.
    ii Crockett, Seth D., et al. American Gastroenterological Association Institute guideline on the medical management of opioid-induced constipation, Gastroenterology 156.1 (2019): 218-226.
    iii Full prescribing information for Movantik (naloxegol) is available at: www.Movantik.com.
    iv Full prescribing information for Talicia (omeprazole magnesium, amoxicillin and rifabutin) is available at: www.Talicia.com.
    v Full prescribing information for Aemcolo (rifamycin) is available at: www.Aemcolo.com.


    Seite 4 von 4



    Diskutieren Sie über die enthaltenen Werte



    globenewswire
    0 Follower
    Autor folgen

    Weitere Artikel des Autors


    Verfasst von globenewswire
    RedHill Biopharma Adds Israel Rights to Movantik From AstraZeneca - Seite 4 RedHill obtains Israel rights to Movantik from AstraZeneca, giving RedHill global rights, excluding Europe and Canada-Movantik approved for opioid-induced constipation in Israel under the brand name Moventig-RedHill to evaluate partnering …